Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
OCTREOTIDE ACETATE
Novartis Pharmaceuticals UK Ltd
H01CB02
OCTREOTIDE ACETATE
30 Milligram
Pdr+Solv for Susp for Inj
Product subject to prescription which may not be renewed (A)
Somatostatin and analogues
Authorised
1998-07-13
1 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT SANDOSTATIN LAR 10 MG POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION SANDOSTATIN LAR 20 MG POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION SANDOSTATIN LAR 30 MG POWDER AND SOLVENT FOR SUSPENSION FOR INJECTION octreotide READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Sandostatin LAR is and what it is used for 2. What you need to know before you use Sandostatin LAR 3. How to use Sandostatin LAR 4. Possible side effects 5. How to store Sandostatin LAR 6. Contents of the pack and other information 1. WHAT SANDOSTATIN LAR IS AND WHAT IT IS USED FOR Sandostatin LAR is a synthetic compound derived from somatostatin. Somatostatin is normally found in the human body, where it inhibits the release of certain hormones such as growth hormone. The advantages of Sandostatin LAR over somatostatin are that it is stronger and its effects last longer. SANDOSTATIN LAR IS USED to treat acromegaly, Acromegaly is a condition where the body produces too much growth hormone. Normally, growth hormone controls growth of tissues, organs, and bones. Too much growth hormone leads to an increase in the size of bones and tissues, especially in the hands and feet. Sandostatin LAR markedly reduces the symptoms of acromegaly, which include headache, excessive perspiration, numbness of the hands and feet, tiredness, and joint pain. In most cases, the overproduction of growth hormone is caused by an enlargement in the pituitary gland (a pituitary adenoma); Sandostat Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Sandostatin LAR 30 mg Powder and Solvent for Suspension for Injection. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One vial contains 30 mg octreotide (as octreotide acetate). Excipients with known effect: Contains less than 1 mmol (23 mg) sodium per dose, i.e. is essentially "sodium free". For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Powder and solvent for suspension for injection. Powder: White to white with yellowish tint. Solvent for suspension for injection: clear, colourless to slightly yellow or brown solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of patients with acromegaly in whom surgery is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective (see section 4.2). Treatment of patients with symptoms associated with functional gastro - entero - pancreatic endocrine tumours e.g. carcinoid tumours with features of the carcinoid syndrome (see section 5.1). Treatment of patients with advanced neuroendocrine tumours of the midgut or of unknown primary origin where non- midgut sites of origin have been excluded. Treatment of TSH - secreting pituitary adenomas: • when secretion has not normalised after surgery and/or radiotherapy; • in patients in whom surgery is inappropriate; • in irradiated patients, until radiotherapy is effective. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Acromegaly_ It is recommended to start treatment with the administration of 20 mg Sandostatin LAR at 4-week intervals for 3 months. Patients on treatment with s.c. Sandostatin can start treatment with Sandostatin LAR the day after the last dose of s.c. Sandostatin. Subsequent dosage adjustment should be based on serum growth hormone (GH) and insulin- like growth factor 1/somatomedin C (IGF - 1) concentrations and clinical symptoms. For patients in whom, within this 3-month period, clinical symptoms and biochemical parameters (GH; IGF - 1) are not fully controlled (GH c Read the complete document